SHIH-JER HSUYu, Ming-LungMing-LungYuSu, Chien-WeiChien-WeiSuPeng, Cheng-YuanCheng-YuanPengChien, Rong-NanRong-NanChienLin, Hsien-HongHsien-HongLinLo, Gin-HoGin-HoLoSu, Wei-WenWei-WenSuKuo, Hsing-TaoHsing-TaoKuoHsu, Chao-WeiChao-WeiHsuYang, Sien-SingSien-SingYangYang, Sheng-ShunSheng-ShunYangTseng, Kuan-ChiaoKuan-ChiaoTsengQin, AlbertAlbertQinYI-WEN HUANGChuang, Wan-LongWan-LongChuang2023-08-162023-08-162021-030929-6646https://www.scopus.com/record/display.uri?eid=2-s2.0-85092660681&doi=10.1016%2fj.jfma.2020.09.018&origin=inward&txGid=735eabc07467c963e6bc1115eab1c260https://scholars.lib.ntu.edu.tw/handle/123456789/634573Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to the 8 to 14 isomers of other on-market pegylated interferon products, allowing every-two-week injection with high tolerability. It received European Medicines Agency marketing authorization in 2019 and Taiwan Biologics License Applications Approval in 2020 for the treatment of polycythemia vera. This study aimed to evaluate the safety and efficacy of Ropeginterferon alfa-2b plus ribavirin in genotype 2 chronic hepatitis C (CHC) patients.enChronic hepatitis C; Genotype 2; Ribavirin; Ropeginterferon alfa-2b; Taiwanjournal article10.1016/j.jfma.2020.09.018330773412-s2.0-85092660681https://api.elsevier.com/content/abstract/scopus_id/85092660681